Clinical applications

 

Understanding the Role of NADs in Modern Medicine 

Redox processes have long been a foundational topic in biochemistry and metabolic research. In clinical practice, however, their translational application has been more limited — due in part to constrained measurement tools and an evolving understanding of their relevance to human health.

Over the past decade, advances in metabolic and redox research have brought these pathways back into sharper clinical focus, offering new perspectives and opportunities for physicians.

At the center of redox balance is NAD (nicotinamide adenine dinucleotide), a key molecule in cellular metabolism and energy production. NAD levels are known to decline in response to physiological stress, acute illness, and chronic disease states.

This section highlights several clinically relevant areas where imbalances in NAD and glutathione are increasingly being explored. These emerging insights may offer additional value for diagnosis, monitoring, and therapeutic decision-making.

VIDEO: Biochemistry and medical experts talk about the NAD measurement in their work. 

ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome)

ME/CFS is increasingly linked to disordered cellular energetics and redox stress. Measuring blood NAD(H)/NADP(H) and glutathione (GSH/GSSG) offers an objective window into energy/redox status that can help stratify patients, guide supportive care, and monitor change over time. While therapeutic standards remain limited, tracking these metabolites reduces trial-and-error and anchors a more evidence-based approach. Emerging work highlights oxidative-stress signatures and kynurenine–tryptophan pathway changes connected to NAD metabolism, further motivating measurement as part of clinical assessment and research.

Sources:

Long COVID (Post-acute sequelae of SARS-CoV-2)

SARS-CoV-2 activates NAD-consuming stress responses (e.g., PARPs) and is associated with depressed NAD⁺ and persistent redox imbalance. Measuring NAD species and glutathione can establish a metabolic baseline, track recovery, and support patient stratification for supportive interventions and trials. This moves follow-up beyond symptoms to objective, longitudinal readouts that complement clinical evaluations and help identify subgroups with sustained bioenergetic stress.

Sources:

Obesity & Metabolic Disease

Obesity stresses energy and redox pathways in adipose, muscle, and liver. Human data show reduced NAMPT/SIRT expression in adipose of people with obesity, while model systems demonstrate that impairing NAMPT disrupts adipocyte function and glucose handling, underscoring the sensitivity of metabolic health to NAD availability. Blood NAD(H)/NADP(H) profiling can flag imbalance, guide vitamin B3 status assessment, and monitor responses to lifestyle or pharmacologic programs targeting insulin sensitivity and inflammation.

Sources:

Mitochondrial Myopathy

Adult-onset mitochondrial myopathy shows systemic NAD deficiency detectable from blood and linked to muscle function. A controlled trial demonstrated that niacin repletion raised blood/tissue NAD and improved functional and metabolic readouts, establishing blood NAD as a meaningful pharmacodynamic marker. Routine measurement of NAD couples and glutathione helps define baseline deficits, titrate supportive measures, and track response, especially useful when tissue sampling is impractical.

Sources:

Parkinson’s Disease

Early human studies suggest nicotinamide riboside (NR) can increase brain NAD and modulate cerebral metabolism (e.g., NADPARK), nominating NAD-repletion biology for further investigation. In research and exploratory care pathways, measuring blood NAD(H)/NADP(H) and glutathione offers a practical pharmacodynamic readout of target engagement and potential stratification by redox stress. Standardized assays enable consistent longitudinal tracking across cohorts and sites.

Sources:

Acute Kidney Injury (AKI) / Kidney Disease

The kidney’s high ATP demand makes it vulnerable to NAD⁺ depletion during injury. Across cohorts, de novo NAD biosynthesis markers predict AKI risk, and subsequent work supports urinary NAD-pathway metabolites as clinical indicators. Measuring circulating NAD species alongside glutathione offers a feasible biomarker approach to map injury phases, stratify risk, and monitor renoprotective strategies targeting redox and bioenergetics.

Sources:

Cancer (Treatment Context)

Cancer and many anticancer therapies impose significant redox strain on tumors and normal tissues. While the clinical use of NAD testing in oncology is evolving, monitoring NAD(H)/NADP(H) and glutathione may help characterize treatment-related redox stress, identify vulnerable patients, and track responses to metabolism-targeted or combination regimens—complementing standard safety and efficacy endpoints as evidence matures.

Sources:

ALS (Amyotrophic Lateral Sclerosis)

ALS features mitochondrial dysfunction and oxidative stress in motor neurons and peripheral tissues. Although definitive NAD-targeted therapies are unproven, redox biology is central to disease mechanisms. Measuring NAD couples and glutathione can document biochemical heterogeneity, follow redox trajectories during multidisciplinary care, and anchor pharmacodynamic endpoints in trials aimed at improving cellular energy resilience.

Sources:

RYR1-Related Myopathies

RYR1 variants disrupt calcium handling and excitation–contraction coupling, producing heterogeneous myopathies and exercise intolerance. Early reports point to NAD⁺ dyshomeostasis and glutathione imbalance in RYR1 disease, nominating redox support as a therapeutic hypothesis. Measuring NAD and glutathione enables documentation of baseline disturbance, subgroup identification, and response tracking during targeted interventions—valuable in a rare, variable condition.

Sources:

Rapid Weight Loss / GLP-1 (Semaglutide) Context

Rapid, pharmacologically aided weight loss can include unintended lean-mass reduction. Given skeletal muscle’s energetic demands, maintaining robust NAD⁺/NADH balance is relevant to function and recovery. Using NAD/glutathione testing alongside body-composition and strength measures can help identify risk, distinguish adaptive from maladaptive changes, and tune nutrition, training, and supplementation to preserve performance while pursuing adipose loss.

Sources:

Addiction (Substance Use Disorders)

Addiction biology intersects with redox and NAD-dependent pathways in the brain’s reward circuitry. Reviews highlight that components of NAD metabolism (e.g., sirtuins/NAMPT) can influence signaling linked to craving and reinforcement, while meta-analyses show oxidative stress is elevated and antioxidant defenses reduced in SUD. Mechanistic work implicates NAMPT in cocaine reward, suggesting NAD biosynthesis affects reinforcement. Measuring NAD(H)/NADP(H) and glutathione (GSH/GSSG) may help profile redox load, stratify patients, and track responses to evidence-based treatments—while noting that “NAD therapy” itself remains unproven clinically.

Sources (annotated):

Fertility (Female & Male)

Reproductive aging is associated with declining ovarian/oocyte NAD⁺, impaired mitochondrial function, and increased redox stress. In mice, NAD repletion (e.g., NMN/NR) restores ovarian NAD, improves oocyte quality, and can rescue fertility; human confirmation is still needed. Reviews now frame NAD decline as a hallmark of ovarian aging and implicate NAD pathways in POI/PCOS contexts. On the male side, abundant evidence links oxidative stress to poorer sperm motility/DNA integrity, positioning glutathione as a key antioxidant defense. Measuring NAD couples and GSH/GSSG can provide objective baselines, support stratification, and track responses alongside established reproductive evaluations.

Sources: